




Progress Report 2011

Mel Spigelman, Co-Chair


Mission

To accelerate the discovery and development of new tuberculosis treatments by bringing together all stakeholder perspectives, including those of the patients, in TB Drug Research and Development



- Resource Gateway
- Catalyst of Dialog and Exchange
- Dynamic and Expanding Network

WGND Organization Updates





TB R&D Weekly Update: Podcast Interview with Dr. Sanjib Bhakta

This week's interview is with Dr. Sanjib Bhakta who is Head of Mycobacteria Research Laboratory, Microbiology, Department of Biological Sciences, Institute of Structural and Molecular Biology at the Birbeck University of London. Dr. Bhakta's Laborat...

[Listen](#)

[View All Podcasts >](#)

MESSAGES TO OUR MEMBERS

Going to Lille? Don't Miss the WGND Annual Meeting and other events!
For more information, click here.

Check out our design for new Clinical Trials Database!

The WGND is developing a series of databases to assist tuberculosis clinical trials. Click "Clinical Research" in nav.

[View All Messages >](#)

Total members: 197

up from 145 last year

FROM THE BLOG



K-RITH Seeking Top Recruits for Research Institute in South Africa

K-RITH invites applications from qualified scientists to serve as assistant, associate, and full investigators. Candidates should be interested in tuberculosis and HIV, and we are seeking scientists with a broad variety of backgrounds. The deadline for filing applications for this round of recruitment is November 1.

Posted 14 October 2011 | No Comments



Winstone's Voice

As has been widely reported, we lost Winstone Zulu, a tireless advocate for TB/HIV. Chief among his gifts was the ability to speak with passion about his subject, finding the precise balance between hard facts, personal history, and an inspiring call to action.

Posted 12 October 2011 | One Comment

GET INVOLVED

 [Sign up for email](#)

 [Add a project](#)

 [Become a member](#)

SITE FEATURES



Global Discovery Programs

An online tool that invites developers to submit their discovery programs so we can provide a more complete snapshot of current global efforts.

[View Discovery](#)



Why We Need New TB Drugs

Today's TB drug regimen takes too long to be effective and requires too many medications. Treatment of drug-sensitive disease requires 6-9 months whereas treatment of drug-resistant TB is even longer, taking 18-24 months or longer.

[Read More](#)

ABOUT US



Our Mission

To accelerate the discovery and development of new drugs for the treatment of tuberculosis by bringing together the stakeholders in TB Drug Development, including the patients themselves.

[Read More >](#)



Global Membership

The WGND is a diverse international group of stakeholders in TB drug development, including those working in regulatory, public health, clinical research, funders, community research, advocates and policy-makers.

[Read More >](#)

Total members:

WGND Members:

William Bishai
Johns Hopkins School of Medicine

[View All Members >](#)


Contacts


434 ACTIVE CONTACTS

 [Add and update contacts](#)

 [Grow my contact list](#)

Major Initiatives





PIPELINE

 Login/Register to add a Project

 Download the PPT Slide

CLINICAL DEVELOPMENT



PRECLINICAL DEVELOPMENT	PHASE I	PHASE II	PHASE III
<p>CPZEN-45 Caprazene nucleoside Microbial Chemistry Research Foundation, Tokyo, Japan, Lilly TB Drug Discovery Initiative, NIAID, IDRI, Lilly, YourEncore</p>	<p>AZD5847 Oxazolidinone Astrazeneca NCE</p>	<p>PA-824 Nitroimidazol-oxazine TB Alliance REG NCE</p>	<p>Gatifloxacin Fluoroquinolones Information provided by WGND</p>
<p>Quinolone DC-159a Fluoroquinolone Antibiotics Japan Anti-Tuberculosis Association, JATA, Daiichi-Sankyo Pharmaceutical Co.</p>		<p>Novel Combinations/Regimens NCE Nitroimidazol-oxazine, diarylquinoline, fluoroquinolone, Nicotinic acid derivative TB Alliance</p>	<p>Moxifloxacin for Drug-Sensitive TB Fluoroquinolones University College London</p>
<p>SQ609 Dipiperidines Sequella</p>		<p>PNU-100480 NCE Oxazolidinone Pfizer</p>	<p>Rifapentine (TBTC Study 26) Rifamycin CDC, Sanofi-aventis</p>
<p>SQ641 Capuramycins Sequella</p>		<p>TMC207 (Bedaquiline) for MDR-TB NCE Diarylquinoline Tibotec BVBA</p>	
<p>BTZ043 GLP Benzothiazinones New Medicines For Tuberculosis (NM4TB)</p>		<p>SQ109 NCE Ethylenediamines Sequella, NIH</p>	
<p>Q201-Novel anti-TB agent Imidazopyridine Quoro Science, Inc.</p>		<p>TMC207(Bedaquiline) for DS-TB NCE Diarylquinoline TB Alliance, Janssen Pharmaceutica N.V.</p>	
		<p>OPC-67683 (Delamanid) NCE Nitro-dihydro-imidazooxazole Otsuka Pharmaceutical Co., Ltd.</p>	
		<p>Linezolid for MDR-TB Oxazolidinones TBTC, Pfizer</p>	
		<p>Rifapentine (TBTC study 29) Rifamycin CDC, Sanofi-aventis</p>	

DISCOVERY PIPELINE

 Login/Register to add a Project

 Download the PPT Slide

HIT-TO-LEAD

LEAD-OPTIMIZATION

Phenotypic Hit-to-Lead

University of Illinois, TB Alliance

M. tuberculosis Protein Kinase Inhibitors

Several chemical scaffolds with various PknA, PknB and PknG selectivity profiles
Vertex Pharmaceuticals, Incorporated

Fungal metabolites

Mycosynthetix, University of Illinois at Chicago

Actinomycete metabolites

University of Illinois at Chicago, Myongji University

DNA metabolism

Novel structural class
AstraZeneca R and D Bangalore

Phenotypic hit to lead

Multiple novel structural classes
Lilly TB Drug Discovery Initiative

Novel hit-lead programs

Novel structural class
Lilly TB Drug Discovery Initiative

Phenotype Hit-to-Lead

Novel structural classes
AstraZeneca R and D Bangalore

Combinatorial Biosynthetic Compounds

Shaw Environmental and University of Illinois at Chicago

Folate Biosynthesis Inhibitors

AstraZeneca, TB Alliance

Phenotypic Hit-to-Lead

GlaxoSmithKline, TB Alliance

Malate Synthase Inhibitors

GlaxoSmithKline, Texas A&M University, TB Alliance

Menaquinone Synthase Inhibitors

Colorado State University, TB Alliance

Inhibitors of Mycobacterium Tuberculosis Energy Metabolism

Various Classes
UPenn and TB Alliance

Inhibitors of isoprenoid biosynthesis

Lilly TB Drug Discovery Initiative

Protein Splicing Inhibitors

Boston Biomedical Research Institute

Nitroimidazoles

Nitroimidazoles
TB Alliance, University of Auckland, University of Illinois

Diarylquinolines

Diarylquinoline
TB Alliance, University of Auckland, Tibotec

Riminophenazines

Riminophenazines antibiotic
TB Alliance, Institute of Materia Medica, The Beijing Tuberculosis and Thoracic Tumor Research Institute and University of Illinois

InhA Inhibitors

Novel structural class
GlaxoSmithKline, TB Alliance

LeuRS Inhibitors

Oxaboroles
Anacor Pharmaceuticals

Mycobacterial Gyrase Inhibitors

Novel structural class
TB Alliance, GlaxoSmithKline

Pyrazinamide Analogs

Pyrazinamide/nicotinamide analogs
TB Alliance/Yonsei University

TL1 Inhibitors

Capuramycins
Sequella

MTopo

Novel structural class
AstraZeneca R and D Bangalore

GyrB Inhibitors

AstraZeneca, TB Alliance

SCAR - Ruthenium (II) phosphine/diimine/picolinate complexes: Inorganic compounds as agents against tuberculosis

Inorganic Compounds
FAPESP/Brazil

Spectinamides

Spectinomycin analogs
St Jude Children's Research Hospital, University of Tennessee Health Science Center, Colorado State University, University of Zurich, Microbiotix



Please Join the
conversation